Get started

GWPH

CDXC: Small Float Biopharma with BIG Potential $20After basing for many years, CDXC is showing signs of awakening. Stocks are being accumulated but not aggressively. It's one of few bio stocks with insider buying at the current price. The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap, with about 62 mil shares O/S. Potentially huge valuation creation. Backed by smart biopharma investors with a tiny float (56% controlled by 20 investors). Their product is patented with an 80% gross margin. It is however a stock for patient investors, not fly by the night type of stocks. It is in my Long Term portfolio.
NASDAQ:CDXCLong
by Jonas99
Bullish news for the cannabis industry.Yesterday’s announcement of a movement towards cannabis legislation has been the best news for the industry since the listing of cannabis stocks. The THCX fund is newer and has a lower market cap then the MJ ETF, it also trades at a lower price making an attractive buy for retail investors. It’s holdings are: APHA Aphria Inc 8.95% 603437 TLRY Tilray Inc 7.83% 333051 CGC Canopy Growth Corp 6.94% 172783 GRW. GROW GENERATION 6.44% 129468 GWPH. GW Pharmaceuticals P 6.16% 32626 VFF Village Farms Intern 5.96% 476411 CRON Cronos Group Inc 5.63% 514377 AMRS Amyris Inc 4.68% 444447 HYFM HYDROFARM 4.67% 62020 Technically speaking, yesterday surge In volume along with positive news is driving the stock higher. If we manage to have a positive close 1/4/21 this could be the start of accumulation, and a move to complete the rounded bottom and test the IPO price, here a cup and handle, or a continuation of the uptrend do to social media, new retail investors, hype, super positive outlook could form. Holding shares
TLong
by Yoimdop3
GWPH accumulation or distribution?A clear uptrend, these past few weeks, it looks like the stock has bottomed and is currently waiting for new momentum. Still extremely overvalued at current market cap of $3B. The company shows excellent growth, however, and with the EU possibly opening up for marketing of Epidiolex this year, we could see growth sustained or even increased. I'm currently hoping for a gap fill, but we seem to have a few very clear ranges and resistance in play. Still, I want to keep an eye on SPY, as the broader markets appear to be headed for a hard correction, which would likely drag GWPH down to retest the lows of around $95. I'm thinking to go long if it breaks the current rising wedge bullish. If it doesn't, I'll stay on the sidelines...
G
by Barkworth
GWPH is a clear buyWow, great trend, much support. Hey, I've said it before I'll say it again, I'm no technical analysis guru. I think most of it is hooplah. Have you ever heard of the guys on Wall Street who threw darts at random stocks on a wall and those picks ended up performing better than most professional hedge fund managers? Yeahhh, exactly. I personally don't believe in most of these unicorn indicators. Goku flying on a Ichimoku cloud over here, fucking RSI up your ass over there. I don't look at any of it. (bUt YoU hAVe tHe RsI uP rIGhT nOw) shhhhhhh it's for giggles. Now let me tell you what I do do (heh heh). I follow a rule I've established with myself before I go in and buy/sell a stock. I only commit to that action of exchanging the stock for cash or vice versa unless my conditions are met. Want to know what those conditions are? PSSHHHH. I'm not telling. Not that you care anyway. I'm not like, the best trader in the world. But I heavily believe part of trading is understanding the psychology of the market and beating the other guy - except for whale behavior but you can argue there's a psychological aspect to that as well (detecting that shit is hard tho) - so telling you my strategy is a joke and that's why I rarely believe in anyone who tells me there's. Anyyyyywho. What I will reveal is my bullishness on GW Pharmaceuticals. I'll even reveal what prices I bought in at - an average cost of $103.13 and I will be buying more good sir. I took a look at this companies balance sheet compared to last year and I swear I got half a chub. For one, GWPH's product Epidolex has competitor advantage being the only FDA approved cannabidiol product to treat two forms of epilepsy in children. Over 18,000 children suffer from LGS and Dravet Syndrome in America (the forms of epilepsy the prescription treats). As of now 7,600 patients have received Epidolex for treatment resulting in $31 million in sales for this product. Future sales can potentially double just for America alone. The company is gearing up in the EU market as well. Not to mention they are testing the same prescription in treating a disease that affects 1-2 million people worldwide. This baby is going to the moon given FDA approval for the treatment. But of course that's an "if". Considering the hard facts I like that the companies' assets are outpacing its liabilities and looking at last years' balance sheet compared to this years' this stock was either grossly over valued last year and slightly under valued this year or damn near bubble euphoria territory last year and fairly priced this year. There could be a third scenario that this stock price is still overvalued but man does this companies growth story look attractive. I'm buying!! P.S - I am a random dude who doesn't know shit about shit. I'm just reading books, reading balance sheets, watching YouTube videos trying to figure out how to value businesses. I got involved in the stock market 3 years ago and I'm just straight up passionate about it dawg. Think it was my real calling truth be told. I'm documenting for future purposes. Follow my trades if you want, just don't cry if you randomly read this and got convinced to buy something because of a stranger. I learned the hard way to never do that again. I only read other peoples recommendations of stocks to get an understanding of how other peeps are valuating companies. I don't even read that trade junk anymore, I've already got my set of rules. And I also only execute very few trades because as we know most traders do not beat the market. If you think you can I encourage you to try to get into an Ivy league cuz you're chances are roughly the same. Good luck out there folks. Holla atcha boy
GLong
by misckid
Perfect Double Bottom for ZYNEDouble bottom in an uptrend: - The double bottom looks like the letter "W". The twice-touched low is considered a support level. - The advance of the first bottom should be a drop of 10% to 20%, then the second bottom should form within 3% to 4% of the previous low, and volume on the ensuing advance should increase. - The double bottom pattern always follows a major or minor downtrend in a particular security, and signals the reversal and the beginning of a potential uptrend. Out of the most interesting cannabis bio pharma companies (GWPH, CARA and ZYNE), this one seems to be ready for another break out. I'm anticipating a quick retrace, then a break through resistance to test the next level. Just my 2 cents. It's free. Trade with caution.
Z
by Barkworth